Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Anebulo Pharmaceuticals (NASDAQ:ANEB) and maintained a price target of $8.
October 01, 2024 | 11:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Anebulo Pharmaceuticals and maintained a price target of $8.
The reiteration of a Speculative Buy rating and maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100